(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.
Cervomed's earnings in 2026 is -$26,966,367.On average, 9 Wall Street analysts forecast CRVO's earnings for 2026 to be -$17,880,438, with the lowest CRVO earnings forecast at -$26,222,544, and the highest CRVO earnings forecast at -$5,249,694. On average, 6 Wall Street analysts forecast CRVO's earnings for 2027 to be -$13,599,206, with the lowest CRVO earnings forecast at -$18,963,708, and the highest CRVO earnings forecast at -$3,305,363.
In 2028, CRVO is forecast to generate -$11,710,428 in earnings, with the lowest earnings forecast at -$19,235,915 and the highest earnings forecast at -$3,499,796.